Research and Markets: Investigation Report on China's Raloxifene Market, 2010-2019
September 03 2015 - 3:04PM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/4lfh89/investigation)
has announced the addition of the "Investigation Report on China's
Raloxifene Market, 2010-2019" report to their offering.
According to the statistics, over 200 million people suffer from
osteoporosis in the world. Among women aged 50 and above in China,
50% have low bone mass or osteoporosis while this figure is 30%-50%
among women aged 60 and above.
Raloxifene (raloxifene hydrochloride), a non-hormone drug
against bone resorption, belongs to the second generation of
selective estrogen receptor modulator (SERMs). Different from
traditional estrogen replacement therapy (ERT) or hormone
replacement therapy (HRT), raloxifene can not only prevent
postmenopausal women from osteoporosis but also effectively
increase bone mass and bone density so as to treat postmenopausal
osteoporosis and prevent osteoporotic fracture.
When raloxifene made by Eli Lilly under the trade name of Evista
entered the market in 1997, its global sales value in the first
year reached up to 285 million, making it the second most
successful product of Eli Lilly. However, raloxifene's annual sales
value has been fluctuating around USD 1 billion after it reached
its sales peak of USD 1.091 billion in 2007.
Raloxifene made by local enterprises came into the market after
Evista entered China in Oct. 2003 and raloxifene's CAGR was about
14% during the period of 2005-2014 according to CRI's survey.
Raloxifene enjoys a vast demand in China. Currently, raloxifene in
the Chinese market is monopolized by the following three companies:
Eli Lilly and Company (Spain), Eli Lilly and Company (UK) and
Jiangsu Hengrui Medicine Co., Ltd, among of which Eli Lilly and
Company (Spain) has the largest market share of 86% for sales value
in 2014.
For more information visit
http://www.researchandmarkets.com/research/4lfh89/investigation
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150903006407/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Pharmaceuticals